- Home
- IOVA vs KOD Comparison
IOVA vs KOD Comparison
Compare IOVA & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- KOD
- Stock Information
- Founded
- IOVA 2007
- KOD 2009
- Country
- IOVA United States
- KOD United States
- Employees
- IOVA N/A
- KOD N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IOVA Health Care
- KOD Health Care
- Exchange
- IOVA Nasdaq
- KOD Nasdaq
- Market Cap
- IOVA 975.1M
- KOD 795.5M
- IPO Year
- IOVA N/A
- KOD 2018
- Fundamental
- Price
- IOVA $2.47
- KOD $22.43
- Analyst Decision
- IOVA Buy
- KOD Buy
- Analyst Count
- IOVA 12
- KOD 7
- Target Price
- IOVA $10.36
- KOD $22.29
- AVG Volume (30 Days)
- IOVA 20.9M
- KOD 798.8K
- Earning Date
- IOVA 11-06-2025
- KOD 11-13-2025
- Dividend Yield
- IOVA N/A
- KOD N/A
- EPS Growth
- IOVA N/A
- KOD N/A
- EPS
- IOVA N/A
- KOD N/A
- Revenue
- IOVA $250,425,000.00
- KOD N/A
- Revenue This Year
- IOVA $65.15
- KOD N/A
- Revenue Next Year
- IOVA $58.47
- KOD N/A
- P/E Ratio
- IOVA N/A
- KOD N/A
- Revenue Growth
- IOVA 175.62
- KOD N/A
- 52 Week Low
- IOVA $1.64
- KOD $1.92
- 52 Week High
- IOVA $9.70
- KOD $23.11
- Technical
- Relative Strength Index (RSI)
- IOVA 57.23
- KOD 68.76
- Support Level
- IOVA $2.09
- KOD $19.25
- Resistance Level
- IOVA $2.55
- KOD $22.14
- Average True Range (ATR)
- IOVA 0.24
- KOD 2.00
- MACD
- IOVA 0.01
- KOD 0.19
- Stochastic Oscillator
- IOVA 61.59
- KOD 99.45
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.